KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Net Margin (2016 - 2025)

Neogenomics' Net Margin history spans 16 years, with the latest figure at 5.2% for Q4 2025.

  • For Q4 2025, Net Margin rose 371.0% year-over-year to 5.2%; the TTM value through Dec 2025 reached 14.85%, down 293.0%, while the annual FY2025 figure was 14.85%, 293.0% down from the prior year.
  • Net Margin reached 5.2% in Q4 2025 per NEO's latest filing, up from 14.45% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 63.61% in Q2 2021 to a low of 42.17% in Q1 2022.
  • Average Net Margin over 5 years is 14.47%, with a median of 16.46% recorded in 2022.
  • Peak YoY movement for Net Margin: soared 7145bps in 2021, then plummeted -9183bps in 2022.
  • A 5-year view of Net Margin shows it stood at 33.21% in 2021, then soared by 51bps to 16.36% in 2022, then soared by 44bps to 9.21% in 2023, then rose by 3bps to 8.91% in 2024, then soared by 42bps to 5.2% in 2025.
  • Per Business Quant, the three most recent readings for NEO's Net Margin are 5.2% (Q4 2025), 14.45% (Q3 2025), and 24.87% (Q2 2025).